Psychedelic Spotlight | Covering The Emerging Psychedelics Industry

Catch up on some of the biggest psychedelic business developments that unfolded in the last week.

Agency argues these five tryptamines "have no known medical use," setting up a showdown with the emerging psychedelics industry.

Americans continue to open their minds to ketamine, psilocybin, and MDMA treatment for depression, anxiety, and PTSD.

The technology may be more broadly used in the future for neuroscientific or physiological studies of brain activity during psychedelic use.

A Republican in Missouri and two Democrats in Virginia file bills that push the psychedelics movement forward.

This week in psychedelic business news: Another psychedelics company starts trading on OTCQB; another ketamine trial delivers; and another patent is issued.

Awakn Life Sciences' Head of Ketamine-Assisted Therapy, Professor Celia Morgan, says world’s first controlled trial to investigate efficacy of ketamine-assisted therapy for treatment of Alcohol Use Disorder "paves the way for a paradigm shift."

California's not alone. Florida, Michigan, New York, and more U.S. states may pass psychedelic therapy or decriminalization legislation in 2022, while Canada kicked off the year with more access.

CEO of Mindset Pharma, James Lanthier, gives us an overview of his company and the 4 new psychedelics they are creating. He also discusses some big breaking news!

Co-Founder and CEO, Matt Stang, gives us an overview of the company's clinics, Delic Labs and more.

Tim Ferriss and Roland Griffiths are among the biggest names in the burgeoning psychedelics movement that are set to appear during the SXSW Conference running from March 11-20.

This week in psychedelic business news: Mindset Pharma partners with global pharmaceutical company; Awakn Life Sciences explores behavioral addictions; Ei.Ventures buys virtual land for psychedelic therapy.

New amendment reverses a 2013 Health Canada policy that prevented "a letter of authorization for a new drug that is or that contains a restricted drug."

The pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.

Since substances such as LSD and psilocybin have powerful anti-inflammatory properties, researchers argue that the microbiological action of psychedelics may therefore help fight brain-based symptoms in early Alzheimer’s patients.

Latest News

psycspotlight